Pfizer's CEO Albert Bourla confirmed the company's application and said in a video statement,  'It is with great pride and joy - and even a little relief - that I can say that our request for emergency use authorization for our COVID-19 vaccine is now in the FDA's hands.'

Pfizer that its EUA submission is supported by solicited safety data from a randomised subset of approximately 8,000 participants aged 18 years or above and unsolicited safety data from approximately 38,000 trial participants

Emboldened, firms indulge in a game of one-upmanship based on alarmingly low number of trials. Sputnik had been tried on only 20 patients before Gamaleya made the claim; Pfizer 120 and Moderna 95

The early results provide strong signals that the coronavirus vaccine could prevent a majority of disease when large groups of people are vaccinated. However, the actual efficacy could be known only after the final results are out once the stage 3 trials end

India Stock Market Highlights Today: Global equities were buoyed today as positive macroeconomic data flow and hopes of a COVID-19 vaccine boosted investor sentiment

Catch top stories from the world of business and economy with BusinessToday.In's Biz EOD report

Moderna stated that its COVID-19 vaccine candidate remains stable for 30 days at 2-degree Celsius to 8-degree Celsius, the temperature of a standard home or medical refrigerator

BioNTech's CEO and Co-founder Ugur Sahin said, if everything continues to go well, the vaccine would begin to be delivered at the \"end of this year, beginning of next year.\"

Under the agreement, the company will commit approximately $604 million and the US govt will commit about $454 million to support the Phase 3 clinical trial

FM Nirmala Sitharaman Press Conference Live: FM Sitharaman's announced several stimulus measures to revive the ecomony on Thursday, November 12. Among several of them, she announced new subsidies for employers and employees under the Atmanirbhar Bharat Rozgar Yojana Subsidy

India Stock Market News Updates Today: SBI, IndusInd Bank and Kotak Bank were among the top Sensex losers today. On the other hand, HUL, ITC and L&T shares ended in green

In a letter to Vardhan last week, Kejriwal cited a shortfall of around 4,900 beds in hospitals, seeking the Union minister's direction to the hospitals run by the central government in Delhi

India may concentrate its efforts on Bharat Biotech's Covaxin as AstraZeneca's COVID-19 vaccine deliveries may be delayed. The months of November and December could be critical in terms of vaccine availability as a number of companies are likely to publish late-stage trial data

The World Economic Forum (WEF) said the latest survey has shown a growing reluctance to receive a vaccine, despite progress made by numerous pharmaceutical companies working on vaccine trials

India Stock Market Highlights Today: Reliance Industries, followed by M&M, Bajaj Auto, Tata Steel, NTPC, Titan and HDFC were among the was the top gainer in the Sensex pack. Tech Mahindra, Nestle India, Bharti Airtel, PowerGrid and Infosys were among the laggards

India Stock Market Highlights Today: SBI, followed by HCL Tech, Tech Mahindra, Asian Paints, Infosys, Tata Steel, TCS and Reliance Industries were among the top gainers in the Sensex pack. On the other hand, ONGC and Titan were the laggards.

Coronavirus crisis: From Thursday all non-essential shops, pubs and restaurants in England will close for four weeks, except where they serve takeaway food

Scientists have developed a vaccine candidate for COVID-19 that produces high levels of antibodies and better immune response in animals. J&J vaccine trials have resumed in Brazil and Mexico has received coronavirus vaccine from CanSino Biologics for late-stage trials

German biotech firm CureVac has revealed its vaccine candidate has triggered an immune response during its phase 1 trials. The UK government has also started the process of the rolling review of AstraZeneca's candidate

The latest beta version of iOS packs a new feature that can help visually impaired users during the novel coronavirus pandemic.